Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 6

Safe and tolerable one-hour pamidronate infusion for multiple myeloma patients

Authors Dimitrios Chantzichristos, Andréasson Björn, Johansson Peter

Published 5 December 2008 Volume 2008:4(6) Pages 1371—1374

DOI https://doi.org/10.2147/TCRM.S4004

Review by Single-blind

Peer reviewer comments 3

Dimitrios Chantzichristos, Andréasson Björn, Johansson Peter

Department of Internal Medicine, Uddevalla Hospital, Uddevalla, Sweden

Background: Once a month, patients with multiple myeloma received an infusion of bisphosphonates, principally to reduce osteoclastic bone resorption. Recommended infusion time for pamidronate is 2 hours in the US and 4 hours in Europe because of its potential nephrotoxicity. From 2003, a 90 mg infusion of pamidronate was provided over 1 hour to patients with no pre-existing renal impairment, in the Daily Care Unit at Uddevalla Hospital.

Method: Retrospective analysis of the renal deterioration, serum calcium, and adverse effects in patients with multiple myeloma treated with 1-hour pamidronate 90 mg infusion from January 2003 to April 2007.

Results: Seventy-nine patients provided valuable data. A total number of 846 infusions were given and the median number of infusion to each patient was 11. Significant creatinine elevation was seen in 7 patients (8.9%), after 19 infusions (2.2%). Renal deterioration occurred in 5 of these 7 patients, which was related to progress of the myeloma or opportunistic infections. Prevalence of infusion-related events was 0.8% and the mean total S-Ca was 0.05 mmol/L lower than the baseline.

Conclusion: Few events of renal deterioration, hypocalcemia, or other adverse effects resulted from a 1-hour pamidronate 90 mg infusion for multiple myeloma patients with no pre-existing renal impairment.

Keywords: bisphosphonates, pamidronate, multiple myeloma, infusion time

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

Binding of plasma proteins to titanium dioxide nanotubes with different diameters

Kulkarni M, Flašker A, Lokar M, Mrak-Poljšak K, Mazare A, Artenjak A, Čučnik S, Kralj S, Velikonja A, Schmuki P, Kralj-Iglič V, Sodin-Semrl S, Iglič A

International Journal of Nanomedicine 2015, 10:1359-1373

Published Date: 18 February 2015

In situ precipitation: a novel approach for preparation of iron-oxide magnetoliposomes

Xia S, Li P, Chen Q, Armah M, Ying X, Wu J, Lai J

International Journal of Nanomedicine 2014, 9:2607-2617

Published Date: 23 May 2014

Chlorotoxin-conjugated graphene oxide for targeted delivery of an anticancer drug

Wang H, Gu W, Xiao N, Ye L, Xu Q

International Journal of Nanomedicine 2014, 9:1433-1442

Published Date: 18 March 2014

NanoDisk containing super aggregated amphotericin B: a high therapeutic index antifungal formulation with enhanced potency

Burgess BL, He Y, Baker MM, Luo B, Carroll SF, Forte TM, Oda MN

International Journal of Nanomedicine 2013, 8:4733-4743

Published Date: 12 December 2013

Development of PLGA-based itraconazole injectable nanospheres for sustained release

Bian X, Liang S, John J, Hsiao CH, Wei X, Liang D, Xie H

International Journal of Nanomedicine 2013, 8:4521-4531

Published Date: 21 November 2013

Topical rebamipide improves the ocular surface in mild lagophthalmos

Itakura M, Itakura H, Kashima T, Akiyama H, Kishi S

Clinical Ophthalmology 2013, 7:1333-1338

Published Date: 1 July 2013